News
ICR cancer drug NXP800 to enter Phase I trials
An investigational drug called NXP800, discovered at the Cancer Research UK Cancer Therapeutics Unit at London’s Institute of Cancer Research (ICR), is to enter Phase I clinical trials in patients with advanced cancers.